Page last updated: 2024-11-04

sb 202190 and Acute Lymphoid Leukemia

sb 202190 has been researched along with Acute Lymphoid Leukemia in 2 studies

4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase

Research Excerpts

ExcerptRelevanceReference
"Acute lymphoblastic leukemia (ALL) is the most common hematological malignancy affecting children."1.34Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy. ( Barredo, JC; Hsieh-Kinser, TT; Leclerc, GJ; Leclerc, GM; Sengupta, TK; Singh, I, 2007)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen-Deutsch, X1
Garay, E1
Zhang, J1
Harrison, JS1
Studzinski, GP1
Sengupta, TK1
Leclerc, GM1
Hsieh-Kinser, TT1
Leclerc, GJ1
Singh, I1
Barredo, JC1

Other Studies

2 other studies available for sb 202190 and Acute Lymphoid Leukemia

ArticleYear
c-Jun N-terminal kinase 2 (JNK2) antagonizes the signaling of differentiation by JNK1 in human myeloid leukemia cells resistant to vitamin D.
    Leukemia research, 2009, Volume: 33, Issue:10

    Topics: Abietanes; Antioxidants; Cell Differentiation; Cell Division; Drug Resistance, Neoplasm; Enzyme Inhi

2009
Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy.
    Molecular cancer, 2007, Jul-10, Volume: 6

    Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Cell Di

2007